BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer.

Combination of BL-8040, KEYTRUDA® and chemotherapy demonstrates a 32% overall response rate and a 77% disease control rate out of 22 currently evaluable patients. Median duration of clinical benefit for all 17 patients with disease control (7 PR and 10 SD patients) is 7.8 months. Patient recruitment nears completion, with 36 out of 40 patients enrolled. Progression free survival and overall survival data remain on track for mid-2020.